SMARCB1 and cyclic hematopoiesis: An actively recruiting study is assessing the safety and tolerability of Tazemetostat monotherapy (BID) and in combination with mAbs (Ipilimumab, Nivolumab) in SMARCA3- or INI1-deficient CH [30].